SSA
ADMS

Schonfeld Strategic Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,627
Closed -$207K – 1047
2018
Q1 		$207K Buy
+8,627
New +$272K 0.02% 685

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Schonfeld Strategic Advisors's ADMS Position: Q2 2018 in Review

Schonfeld Strategic Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q2 2018, closing a stake of 8,627 shares — an estimated $207K sold.

Schonfeld Strategic Advisors first reported a position in ADMS in Q1 2018 and held it in 1 quarter. The position peaked at $207K in Q1 2018. 126 funds tracked by Wall St. Rank hold ADMS as of Q2 2018.

  • Schonfeld Strategic Advisors reported no remaining Adamas Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 8,627 Adamas Pharmaceuticals shares in Q2 2018, an estimated $207K.
  • Schonfeld Strategic Advisors first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Adamas Pharmaceuticals position peaked at $207K in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2018.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.